Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Bleomycin | The risk or severity of adverse effects can be increased when Sargramostim is combined with Bleomycin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sargramostim. |
| Vindesine | The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vindesine. |
| Vinorelbine | The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vinorelbine. |
| Vincristine | The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vincristine. |
| Vinblastine | The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vinblastine. |
| Vintafolide | The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vintafolide. |
| Vinflunine | The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vinflunine. |
| Vincamine | The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vincamine. |